Oxford Biomedica – Half Year Trading Update and Notice of Interim Results Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...

Oxford Biomedica to host webinar showcasing the TetraVecta™ system Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...

Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Bedford, Massachusetts – September 14, 2022: Oxford Biomedica Solutions LLC, an Oxford...

Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc...